⚠ Evidence warning: Clinical trials or other evidence do not support the claims that a low-oxalate diet and low-dose naltrexone relieve vulvodynia. This page keeps it as a report of what people, websites or other media say.

Vulvodynia

Table of Contents

  1. Overview and Definition
  2. Classification: Provoked vs Generalized
  3. Causes and Contributing Factors
  4. Symptoms
  5. Diagnosis
  6. Pelvic Floor Dysfunction
  7. Topical and Local Treatments
  8. Systemic Treatments
  9. Low-Oxalate Diet and Lifestyle
  10. Vestibulectomy
  11. Psychosexual Impact and Support
  12. Prognosis
  13. Non-Drug Options Studied in Recent Trials
  14. Key Research Papers
  15. Connections
  16. Featured Videos

Overview and Definition

Vulvodynia is a chronic vulvar pain disorder lasting at least 3 months, without an identifiable cause on examination or laboratory testing that would fully explain it. It is defined by the International Society for the Study of Vulvovaginal Disease (ISSVD) as vulvar pain of at least 3 months' duration, in the absence of relevant visible findings or a specific, clinically identifiable neurological disorder.

Vulvodynia affects an estimated 8–16% of women at some point in their lives, making it one of the most common causes of vulvar pain — yet it remains profoundly underdiagnosed and undertreated. In a Boston population study, nearly 40% of women with chronic vulvar pain chose not to seek treatment, and of those who did, 60% saw 3 or more doctors, many of whom could not provide a diagnosis. In a Michigan population study, 48.6% of the women meeting the criteria had sought treatment and only 1.4% had been diagnosed with vulvodynia. Many women report being told that "nothing is wrong" or that the pain is psychological. Vulvodynia is a real, physical condition with identifiable neurobiological, musculoskeletal, and hormonal contributors.

The name derives from the Latin vulva and Greek odyne (pain). Historical terms including "vulvodynia" (as a catch-all), "vulvar vestibulitis syndrome," and "essential vulvodynia" have been standardized by the ISSVD into a classification by site (localized vs. generalized) and provocation (provoked vs. spontaneous vs. mixed).

Classification: Provoked vs Generalized

The ISSVD 2015 classification organizes vulvodynia along two axes: anatomical site and stimulus relationship.

By Anatomical Site

By Stimulus Relationship

Primary vs Secondary PVD

Causes and Contributing Factors

Vulvodynia is almost certainly multifactorial, with different contributors playing different roles in different women. No single cause has been established, and the disorder is best understood as a central and peripheral pain sensitization syndrome with several entry points.

Neuroproliferative / Peripheral Sensitization

Hormonal Factors

Pelvic Floor Dysfunction

Genetic and Immune Factors

Recurrent Candidal Vulvovaginitis

Central Sensitization

Symptoms

Diagnosis

Vulvodynia is a diagnosis of exclusion: identifiable causes of vulvar pain are ruled out before the diagnosis is made. The clinical workup includes:

History

Physical Examination

Laboratory Testing

Conditions to Exclude

Pelvic Floor Dysfunction

Pelvic floor physical therapy (PT) is the single most evidence-backed first-line treatment for PVD, with a 50–80% response rate in randomized and observational studies. The hypertonic pelvic floor found in most women with PVD is both a consequence of chronic pain and a perpetuating cause — making PT essential regardless of which other treatments are used.

A multicenter head-to-head trial enrolled 212 women in Canada and compared 10 weeks of weekly multimodal physical therapy (education, pelvic floor exercises with biofeedback, manual therapy and dilation) with overnight 5% lidocaine ointment. Pain during intercourse ended 1.8 points lower on a 0–10 scale with physical therapy, and the difference held at 6 months. At the end of treatment, 79% of the physical therapy group felt very much or much improved, compared with 39% of the lidocaine group. The trial had no placebo group.

Topical and Local Treatments

Systemic Treatments

Two of the common pills have been tested against placebo with negative results. Extended-release gabapentin (1,200–3,000 mg/day) was no better than placebo for tampon-test pain in a crossover trial of 89 women (4.0 compared with 4.3 on a 0–10 scale). Desipramine, a tricyclic antidepressant, was no better than placebo in a 133-woman trial (24% compared with 33% pain reduction). A 2026 network meta-analysis concluded that commonly prescribed drugs "lack robust evidence of superiority over placebo." Placebo alone gave a 33% pain reduction in that desipramine trial, and its authors put the improvement seen in every group down to placebo or placebo-independent effects, so a success rate from a study with no comparison group can reflect those effects as well.

Low-Oxalate Diet and Lifestyle

The low-oxalate diet for vulvodynia is based on the hypothesis that urinary oxalate crystals irritate the vestibular tissue, contributing to pain. While the mechanism remains debated and evidence is observational rather than from randomized trials, many women report symptom relief. The diet is nutritionally safe when managed carefully.

Vestibulectomy

Vestibulectomy — specifically modified posterior vestibulectomy with vaginal advancement — is a surgical procedure that removes the hypersensitive, nerve-dense vestibular tissue and advances the vaginal mucosa to cover the defect. It is indicated for localized PVD that has failed conservative management (pelvic PT, topical/systemic medications) for at least 6 months.

Psychosexual Impact and Support

Vulvodynia profoundly affects sexuality, relationships, and mental health. The psychosexual impact is not a cause of vulvodynia but an important comorbidity that, if unaddressed, perpetuates the pain cycle.

Prognosis

Vulvodynia is a treatable condition — not a life sentence of pain. Prognosis is strongly related to access to informed, multidisciplinary care.

Non-Drug Options Studied in Recent Trials

A 2024 meta-analysis of 9 randomized trials (332 patients) found that rehabilitation treatments lowered pain during intercourse more than placebo, sham treatment or a waiting list, with significant effects for acupuncture and for shockwave therapy. Its authors call for further evidence.

A 2026 network meta-analysis compared treatments across 33 studies and 1,873 women. "Tissue-based" treatments (low-level laser and other light therapy, nerve stimulation through the vagina, and shockwave therapy) were the only group clearly better than placebo, with moderate confidence, right after treatment and again at 3–6 months. Compared with no treatment at all, physical therapy, acupuncture and psychological approaches also reduced pain, with low to moderate confidence.

Key Research Papers

  1. Bornstein J, Goldstein AT, Stockdale CK, et al. 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. Obstetrics & Gynecology. 2016;127(4):745–751. — PubMed PMID: 27008217 · doi:10.1097/aog.0000000000001359
  2. Reed BD, Harlow SD, Sen A, Legocki LJ, Edwards RM, Arato N, Haefner HK. Prevalence and Demographic Characteristics of Vulvodynia in a Population-Based Sample. American Journal of Obstetrics & Gynecology. 2012;206(2):170.e1–9. — PubMed PMID: 21963307 · doi:10.1016/j.ajog.2011.08.012
  3. Harlow BL, Stewart EG. A Population-Based Assessment of Chronic Unexplained Vulvar Pain: Have We Underestimated the Prevalence of Vulvodynia? Journal of the American Medical Women's Association. 2003;58(2):82–88. — PubMed PMID: 12744420
  4. Goldstein AT, Pukall CF, Brown C, Bergeron S, Stein A, Kellogg-Spadt S. Vulvodynia: Assessment and Treatment. Journal of Sexual Medicine. 2016;13(4):572–590. — PubMed PMID: 27045258 · doi:10.1016/j.jsxm.2016.01.020
  5. Bergeron S, Binik YM, Khalife S, et al. A Randomized Comparison of Group Cognitive-Behavioral Therapy, Surface Electromyographic Biofeedback, and Vestibulectomy in the Treatment of Dyspareunia Resulting from Vulvar Vestibulitis. Pain. 2001;91(3):297–306. — PubMed PMID: 11275387 · doi:10.1016/s0304-3959(00)00449-8
  6. Pukall CF, Goldstein AT, Bergeron S, et al. Vulvodynia: Definition, Prevalence, Impact, and Pathophysiological Factors. Journal of Sexual Medicine. 2016;13(3):291–304. — PubMed PMID: 26944461 · doi:10.1016/j.jsxm.2015.12.021
  7. Goldstein AT, Belkin ZR, Krapf JM, et al. Polymorphisms of the Androgen Receptor Gene and Hormonal Contraceptive Induced Provoked Vestibulodynia. Journal of Sexual Medicine. 2014;11(11):2764–2771. — PubMed PMID: 25187224 · doi:10.1111/jsm.12668
  8. Landry T, Bergeron S, Dupuis MJ, Desrochers G. The Treatment of Provoked Vestibulodynia: A Critical Review. Clinical Journal of Pain. 2008;24(2):155–171. — PubMed PMID: 18209522 · doi:10.1097/ajp.0b013e31815aac4d
  9. Haefner HK, Collins ME, Davis GD, et al. The Vulvodynia Guideline. Journal of Lower Genital Tract Disease. 2005;9(1):40–51. — PubMed PMID: 15870521 · doi:10.1097/00128360-200501000-00009
  10. Bohm-Starke N, Hilliges M, Falconer C, Rylander E. Increased Intraepithelial Innervation in Women with Vulvar Vestibulitis Syndrome. Gynecologic and Obstetric Investigation. 1998;46(4):256–260. — PubMed PMID: 9813445 · doi:10.1159/000010045
  11. ter Kuile MM, van Lankveld JJ, de Groot E, Melles R, Neffs J, Zandbergen M. Cognitive-Behavioral Therapy for Women with Lifelong Vaginismus: Process and Prognostic Factors. Behaviour Research and Therapy. 2007;45(2):359–373. — PubMed PMID: 16701078 · doi:10.1016/j.brat.2006.03.013
  12. Brauer M, ter Kuile MM, Laan E. Effects of Appraisal of Sexual Stimuli on Sexual Arousal in Women with and without Superficial Dyspareunia. Archives of Sexual Behavior. 2009;38(4):476–485. — PubMed PMID: 18561015 · doi:10.1007/s10508-008-9371-8
  13. Zolnoun DA, Hartmann KE, Steege JF. Overnight 5% Lidocaine Ointment for Treatment of Vulvar Vestibulitis. Obstetrics & Gynecology. 2003;102(1):84–87. — PubMed PMID: 12850611 · doi:10.1016/s0029-7844(03)00368-5
  14. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, Poleshuck EL, Stodgell CJ, Dworkin RH. Oral Desipramine and Topical Lidocaine for Vulvodynia: A Randomized Controlled Trial. Obstetrics & Gynecology. 2010;116(3):583–593. — PubMed PMID: 20733439 · doi:10.1097/AOG.0b013e3181e9e0ab
  15. Brown CS, Bachmann GA, Wan J, Foster DC; Gabapentin (GABA) Study Group. Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial. Obstetrics & Gynecology. 2018;131(6):1000–1007. — PubMed PMID: 29742655 · doi:10.1097/AOG.0000000000002617
  16. Morin M, Dumoulin C, Bergeron S, Mayrand MH, Khalifé S, Waddell G, Dubois MF; PVD Study Group. Multimodal Physical Therapy Versus Topical Lidocaine for Provoked Vestibulodynia: A Multicenter, Randomized Trial. American Journal of Obstetrics & Gynecology. 2021;224(2):189.e1–189.e12. — PubMed PMID: 32818475 · doi:10.1016/j.ajog.2020.08.038
  17. Spinillo A, Dominoni M, Tiranini L, Cassani C, Nappi RE, Gardella B. Beyond the Placebo Effect: A Systematic Review and a Network Meta-Analysis of Treatment Strategies for Vulvodynia. BMC Women's Health. 2026;26(1):249. — PubMed PMID: 41975391 · doi:10.1186/s12905-026-04469-0
  18. Calafiore D, Marotta N, Curci C, Agostini F, De Socio RI, Inzitari MT, Ferraro F, Bernetti A, Ammendolia A, de Sire A. Efficacy of Rehabilitative Techniques on Pain Relief in Patients With Vulvodynia: A Systematic Review and Meta-Analysis. Physical Therapy. 2024;104(7):pzae054. — PubMed PMID: 38564267 · doi:10.1093/ptj/pzae054
  19. Gao Z, Hu L, Yi C, Gao C. Clinical Impacts of Botulinum Toxin Type A Injections for Provoked Vestibulodynia: Insights From Randomized Controlled Trials. BMC Women's Health. 2025;25(1):590. — PubMed PMID: 41339844 · doi:10.1186/s12905-025-04156-6
  20. Haraldson P, Mühlrad H, Heddini U, Nilsson K, Bohm-Starke N. Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial. Obstetrics & Gynecology. 2020;136(3):524–532. — PubMed PMID: 32769643 · doi:10.1097/AOG.0000000000004008
  21. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum Toxin Type A-a Novel Treatment for Provoked Vestibulodynia? Results From a Randomized, Placebo Controlled, Double Blinded Study. Journal of Sexual Medicine. 2009;6(9):2523–2537. — PubMed PMID: 19619148 · doi:10.1111/j.1743-6109.2009.01378.x
  22. Pelletier F, Gallais Sérézal I, Puyraveau M, Leroux F, Verollet D, Aubin F, Amarenco G, Parratte B. Electromyography-Guided Botulinum Toxin Injections in Provoked Vestibulodynia: A Randomized Double-Blind Placebo-Controlled Clinical Trial. American Journal of Obstetrics & Gynecology. 2026;234(5):1362–1369. — PubMed PMID: 41419152 · doi:10.1016/j.ajog.2025.12.037
  23. Reed BD, Harlow SD, Plegue MA, Sen A. Remission, Relapse, and Persistence of Vulvodynia: A Longitudinal Population-Based Study. Journal of Women's Health. 2016;25(3):276–283. — PubMed PMID: 26752153 · doi:10.1089/jwh.2015.5397
  24. Bouchard C, Brisson J, Fortier M, Morin C, Blanchette C. Use of Oral Contraceptive Pills and Vulvar Vestibulitis: A Case-Control Study. American Journal of Epidemiology. 2002;156(3):254–261. — PubMed PMID: 12142260 · doi:10.1093/aje/kwf037
  25. Reed BD, Harlow SD, Legocki LJ, Helmuth ME, Haefner HK, Gillespie BW, Sen A. Oral Contraceptive Use and Risk of Vulvodynia: A Population-Based Longitudinal Study. BJOG. 2013;120(13):1678–1684. — PubMed PMID: 23937077 · doi:10.1111/1471-0528.12407
  26. Harlow BL, Vitonis AF, Stewart EG. Influence of Oral Contraceptive Use on the Risk of Adult-Onset Vulvodynia. Journal of Reproductive Medicine. 2008;53(2):102–110. — PubMed PMID: 18357801
  27. Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Small MJ, Gelone SP. Cromolyn Cream for Recalcitrant Idiopathic Vulvar Vestibulitis: Results of a Placebo Controlled Study. Sexually Transmitted Infections. 2001;77(1):53–57. — PubMed PMID: 11158692 · doi:10.1136/sti.77.1.53
  28. Crisp CC, Vaccaro CM, Estanol MV, Oakley SH, Kleeman SD, Fellner AN, Pauls RN. Intra-Vaginal Diazepam for High-Tone Pelvic Floor Dysfunction: A Randomized Placebo-Controlled Trial. International Urogynecology Journal. 2013;24(11):1915–1923. — PubMed PMID: 23681047 · doi:10.1007/s00192-013-2108-9
  29. Caravaca F, Ruiz AB, Escola JM, Hernández Gallego R, Cerezo I, Fernández N, Barroso S, Martín MV. Either Calcium Carbonate or Sevelamer Decreases Urinary Oxalate Excretion in Chronic Renal Failure Patients [in Spanish]. Nefrología. 2007;27(4):466–471. — PubMed PMID: 17944584
  30. Coryn N, Vergauwe B, Weyers S, Verstraelen H. Long-Term Effectiveness of Vestibulectomy for the Treatment of Vulvodynia: A Retrospective Cohort Study. Journal of Lower Genital Tract Disease. 2024;28(3):258–263. — PubMed PMID: 38864720 · doi:10.1097/LGT.0000000000000810
  31. Bergeron S, Vaillancourt-Morel MP, Corsini-Munt S, Steben M, Delisle I, Mayrand MH, Rosen NO. Cognitive-Behavioral Couple Therapy Versus Lidocaine for Provoked Vestibulodynia: A Randomized Clinical Trial. Journal of Consulting and Clinical Psychology. 2021;89(4):316–326. — PubMed PMID: 34014693 · doi:10.1037/ccp0000631
  32. Brotto LA, Bergeron S, Zdaniuk B, Basson R. Mindfulness and Cognitive Behavior Therapy for Provoked Vestibulodynia: Mediators of Treatment Outcome and Long-Term Effects. Journal of Consulting and Clinical Psychology. 2020;88(1):48–64. — PubMed PMID: 31841023 · doi:10.1037/ccp0000473

PubMed Topic Searches

  1. PubMed: Vulvodynia
  2. PubMed: Provoked vestibulodynia
  3. PubMed: Vulvar vestibulitis syndrome
  4. PubMed: Vulvodynia pelvic floor therapy
  5. PubMed: Vestibulectomy dyspareunia
  6. PubMed: Low oxalate diet vulvodynia
  7. PubMed: Vulvodynia tricyclic antidepressants
  8. PubMed: Pelvic floor dysfunction dyspareunia
  9. PubMed: Vulvodynia oral contraceptive
  10. PubMed: Vulvar pain central sensitization

Back to Table of Contents

Connections

Back to Table of Contents